BioCorRx (BICX) Stock Overview
Through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BICX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioCorRx Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.29 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.20 |
| Beta | 0.14 |
| 1 Month Change | -29.70% |
| 3 Month Change | -20.06% |
| 1 Year Change | -10.73% |
| 3 Year Change | -86.74% |
| 5 Year Change | -85.96% |
| Change since IPO | -90.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| BICX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 9.8% | 1.1% | 0.4% |
| 1Y | -10.7% | -26.4% | 21.6% |
Return vs Industry: BICX exceeded the US Healthcare industry which returned -27.8% over the past year.
Return vs Market: BICX underperformed the US Market which returned 19.5% over the past year.
Price Volatility
| BICX volatility | |
|---|---|
| BICX Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine BICX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Lourdes Felix | www.biocorrx.com |
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; and the UnCraveRx weight loss program, a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. It also develops BICX101, an injectable and implantable naltrexone product; BICX102, a long-acting naltrexone implant that can last several months for opioid dependence and alcohol use disorders; and BICX104, a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of alcohol and opioid use disorder.
BioCorRx Inc. Fundamentals Summary
| BICX fundamental statistics | |
|---|---|
| Market cap | US$8.56m |
| Earnings (TTM) | -US$4.73m |
| Revenue (TTM) | US$313.14k |
Is BICX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BICX income statement (TTM) | |
|---|---|
| Revenue | US$313.14k |
| Cost of Revenue | US$0 |
| Gross Profit | US$313.14k |
| Other Expenses | US$5.04m |
| Earnings | -US$4.73m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,509.51% |
| Debt/Equity Ratio | -21.2% |
How did BICX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/05 15:12 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCorRx Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Ajay Tandon | SeeThruEquity, LLC |